Introduction
The incidence of endometrial carcinoma, already the most common malignancy of the female pelvis and the fourth most common cancer among women in the United States, has been increasing steadily during the last three decades [
1]. In approximately 75% of patients, the tumor is still confined to the uterus at diagnosis (FIGO stage I), and thus, there is a good prognosis [
2]. However, the prognosis for advanced endometrial carcinomas, with extra-pelvic metastatic dissemination, is extremely poor, and the 5-year survival rate is a mere 5–32% [
1]. Irradiation was usually performed as post-operative adjuvant therapy for early cases considered being at risk of recurrence and for most advanced cases [
3]. Recently, systemic adjuvant chemotherapy, compared to adjuvant irradiation, was reported to significantly improve the prognosis of these cases [
4,
5].
About one-fourth of those patients, treated for what was thought to be an early-stage endometrial cancer, go onto develop a recurrence. Unfortunately, 3–19 years after treatment for the recurrence, only 7.7% of the patients were alive and without evidence of disease [
3]. Recurrences, restricted to the vaginal vault, are relatively better treated with radiotherapy. However, in most cases of relapse, the disease had spread to other sites, including pelvic and para-aortic lymph nodes, the peritoneum of the pelvis and abdominal cavity, and the lungs. For these cases, systemic chemotherapy is usually required.
Cisplatin and doxorubicin were shown to be the most effective drugs for both advanced and recurrent endometrial carcinomas; paclitaxel was also reported to be useful [
6,
7]. A Gynecologic Oncology Group’s (GOG) study showed that a tripartite regimen of the Taxane paclitaxel, plus the Anthracycline doxorubicin and the Platinum drug cisplatin (TAP), provided a better response, as measured by progression-free and overall survival rates, than without the taxane (AP). However, there were significant adverse side effects in the TAP group [
8]. A modified TAP regimen, with the Taxane paclitaxel and Epirubicin (a semi-synthetic stereoisomer of doxorubicin) plus the Platinum drug cisplatin (TEP), was a more effective combination chemotherapy, with a 73% response rate for advanced endometrial carcinomas, suggesting a possible future role of TEP therapy as the first-line treatment for advanced endometrial carcinomas [
9]. A combination chemotherapy of the Taxane paclitaxel and Carboplatin (TC), which is a standard regimen for ovarian carcinoma, was also shown to be a well-tolerated, active adjuvant therapy regimen for advanced endometrial carcinomas [
10]. More recently, a combination chemotherapy of the Taxane paclitaxel, Epirubicin and Carboplatin (TEC) was demonstrated to be active and tolerable in patients with advanced metastatic and recurrent endometrial carcinomas [
11].
Based on these findings, a combined chemotherapy of taxane and platinum, with or without anthracycline, has been used as a standard first-line regimen for both unresected and recurrent endometrial carcinomas and also as an adjuvant therapy for resected cases with a high risk of recurrence. However, a second-line regimen for the treatment of advanced or recurrent endometrial carcinoma previously treated with a combined chemotherapy of taxane and platinum, with or without anthracycline, has yet to be established. We hoped our findings would change that. In our current study, the effectiveness of second-line chemotherapy and the various clinical factors that associate with the prognosis of advanced or recurrent endometrial carcinoma previously treated with a combination chemotherapy of taxane and platinum, with or without anthracycline, were retrospectively investigated.
Conclusions
Endometrial adenocarcinoma is increasingly the most common malignancy of the female pelvis in the United States [
1]. Although early-stage endometrial carcinomas have a good prognosis [
2], the prognoses for advanced or recurrent cases are extremely poor (except for recurrences limited to the vaginal vault, which can generally be treated successfully with surgery and radiation therapy) [
3]. Although a truly successful treatment for advanced or recurrent endometrial carcinomas has yet to be established, taxane and platinum (with or without anthracycline, TC/TEC) have demonstrated at least a partial efficacy [
6‐
11].
Recently, based on these findings, the combined chemotherapy of TC/TEC has been used as a standard first-line regimen for unresected and recurrent endometrial carcinomas as well as an adjuvant therapy for resected cases with a high risk of recurrence. However, an effective second-line regimen for advanced or recurrent endometrial carcinomas previously treated with TC/TEC has not yet been established.
In our present study, we analyzed the outcomes of patients who, after having received a first-line TC or TEC chemotherapy, received a variety of second-line chemotherapy against relapsed or recurrent tumors. The overall response rate to second-line chemotherapy was 25% (0–38%). The PFS was 3.5 months (0–20 months), and the OS was 10 months (2–44 months). The response rates, PFS and OS did not differ significantly by the regimen of second-line chemotherapy. Therefore, other factors associated with the response to second-line chemotherapy were investigated.
In the related field of ovarian carcinomas, a TFI has consistently been shown to be the most important factor in the prediction of the response to the second-line chemotherapy [
21‐
24]. Patients with ovarian tumor who relapse within 6 months have a disease that is significantly more likely to be both resistant to the original drugs and to have a lower response rate to new chemotherapy; however, those who relapse after 6 months from a first-line platinum-based chemotherapy have a higher chance of responding well, either to a re-challenge with a platinum-based treatment or to other agents [
21].
However, comparable predictive factors for the response to second-line chemotherapy have not been established for endometrial carcinomas. It was yet to be determined whether TFI predicts a response to second-line chemotherapy, and if so, whether 6 months was a reasonable critical threshold that would suggest the clinical outcome after second-line chemotherapy. It was also unclear which current regimen is most effective as a second-line chemotherapy for endometrial carcinoma.
In our study, a TFI greater or less than 6 months was demonstrated to be significantly associated with the tumor’s likely responsiveness to a second-line chemotherapy (P = 0.0026 by Fisher’s exact test). The current study also showed that the association between TFI and sensitivity to a second-line TECm, TCm or TCw was statistically significant (P = 0.015 by Fisher’s exact test), indicating that second-line chemotherapy using taxane and platinum, with or without anthracycline, was not effective for those whose TFI was shorter than 6 months after initial treatment using taxane and platinum, with or without anthracycline.
PFS and OS were also shown to relate to a TFI ≥ or <6 months (P = 0.0003 and P = 0.025, respectively, by the log-rank test). As in ovarian tumors, multivariate analysis showed that the TFI for endometrial tumors was also the most significant factor for predicting the effectiveness of a second-line chemotherapy (the adjusted HR of TFI (≥6 months versus <6 months) on PFS: 3.482 (95% CI, 1.641–7.388), and that on OS: 2.341 (95% CI, 1.034–5.301)). TFI was demonstrated to be a significant factor in predicting for PFS and OS (P = 0.0012 and P = 0.042, respectively, based on the multivariate Cox proportional hazards model).
These results imply, for the first time, that the standard strategy for ovarian carcinoma second-line chemotherapy can now be applied to endometrial carcinoma as well. Endometrial carcinomas that relapse at least 6 months after first-line chemotherapy using TC/TEC have a significantly higher chance of responding to second-line chemotherapy. However, the tumors that relapse before 6 months are likely to be resistant. In fact, none of the currently popular regimens of chemotherapy (including the same as, or other than, the first-line regimen) were effective, and the PFS and OS were only 2 months (0–9 months) and 5.5 months (2–44 months), respectively (data not shown). Palliative care in these cases, rather than second-line chemotherapy, may for now be more appropriate.
Our present study provides, for the first time, good evidence that relapsed or recurrent diseases found within 6 months from a first-line chemotherapy regimen using taxane and platinum (with or without anthracycline) fail to respond to second-line chemotherapy. Further investigation is still required to establish an efficacious strategy for second-line chemotherapy for advanced or recurrent endometrial cancer.